Japan Ankylosing Spondylitis Market Size & Outlook

The ankylosing spondylitis market in Japan is expected to reach a projected revenue of US$ 416.5 million by 2027. A compound annual growth rate of 10.3% is expected of Japan ankylosing spondylitis market from 2020 to 2027.
Revenue, 2019 (US$M)
$189.5
Forecast, 2027 (US$M)
$416.5
CAGR, 2020 - 2027
10.3%
Report Coverage
Japan

Japan ankylosing spondylitis market highlights

  • The Japan ankylosing spondylitis market generated a revenue of USD 189.5 million in 2019 and is expected to reach USD 416.5 million by 2027.
  • The Japan market is expected to grow at a CAGR of 10.3% from 2020 to 2027.
  • In terms of segment, humira was the largest revenue generating drug in 2019.
  • Others Drugs is the most lucrative drug segment registering the fastest growth during the forecast period.

Ankylosing spondylitis market data book summary

Market revenue in 2019USD 189.5 million
Market revenue in 2027USD 416.5 million
Growth rate10.3% (CAGR from 2019 to 2027)
Largest segmentHumira
Fastest growing segmentOthers Drugs
Historical data2016 - 2018
Base year2019
Forecast period2020 - 2027
Quantitative unitsRevenue in USD million
Market segmentationCosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia, Others Drugs
Key market players worldwideAbbVie Inc, Amgen Inc, Pfizer Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Johnson & Johnson, Merck & Co Inc

Other key industry trends

  • In terms of revenue, Japan accounted for 4.5% of the global ankylosing spondylitis market in 2019.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
  • In Asia Pacific, Japan ankylosing spondylitis market is projected to lead the regional market in terms of revenue in 2027.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 254.7 million by 2027.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Ankylosing Spondylitis Market Companies

Name Profile # Employees HQ Website

Japan ankylosing spondylitis market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ankylosing spondylitis market will help companies and investors design strategic landscapes.


Humira was the largest segment with a revenue share of 24.49% in 2019. Horizon Databook has segmented the Japan ankylosing spondylitis market based on cosentyx, humira, simponi, remicade, enbrel, cimzia, others drugs covering the revenue growth of each sub-segment from 2016 to 2027.


  • Japan Ankylosing Spondylitis Drug Outlook (Revenue, USD Million, 2016-2027)
    • Cosentyx
    • Humira
    • Simponi
    • Remicade
    • Enbrel
    • Cimzia
    • Others Drugs

Reasons to subscribe to Japan ankylosing spondylitis market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan ankylosing spondylitis market databook

  • Our clientele includes a mix of ankylosing spondylitis market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan ankylosing spondylitis market, including forecasts for subscribers. This country databook contains high-level insights into Japan ankylosing spondylitis market from 2016 to 2027, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Japan ankylosing spondylitis market size, by drug, 2016-2027 (US$M)

Japan Ankylosing Spondylitis Market Share, 2019 & 2027 (US$M)

Japan ankylosing spondylitis market size, by drug, 2016-2027 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more